Joshua Holyoak, MD
Urology · West Jordan, UTNPI 1407071665
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,114 of the $6,146 with a category attached, or 66.9%. 36 manufacturers reported payments, led by Boston Scientific at 24.2% of the total. Reporting peaked in 2019 at $2,793 and has fallen 54.4% since, to $1,272 in 2025.
Across 152 payments — averaging $40.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Neotract Inc.$1K
- Astellas Pharma US Inc$445
- Ferring Pharmaceuticals Inc.$315
- Teleflex LLC$307
- AbbVie$299
- plus $2K from 30 others
What the payments were for
- Travel & lodging$1,70728%
- Food & beverage$4,11467%
- Education$3055%
- Other$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $1,486 |
| Neotract Inc. | 11 | $1,383 |
| Astellas Pharma US Inc | 12 | $445 |
| Ferring Pharmaceuticals Inc. | 7 | $315 |
| Teleflex LLC | 7 | $307 |
| AbbVie(2 entities) | 18 | $299 |
| Axonics, Inc. | 13 | $291 |
| Calyxo, Inc. | 3 | $291 |
| Endo Pharmaceuticals Inc. | 13 | $280 |
| Bayer | 5 | $132 |
| Sumitomo Pharma America, Inc. | 5 | $107 |
| Amgen | 2 | $95 |
| Coloplast | 1 | $76 |
| Urogen Pharma, Inc. | 3 | $71 |
| Valencia Technologies Corporation | 1 | $49 |
| Endo USA, Inc. | 3 | $46 |
| Merck | 2 | $41 |
| Dendreon Pharmaceuticals LLC | 2 | $40 |
| AstraZeneca | 1 | $35 |
| Vertex | 2 | $34 |
| Novo Nordisk | 2 | $34 |
| Pacira Pharmaceuticals Incorporated | 1 | $31 |
| Pfizer | 2 | $28 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| Procept Biorobotics Corporation | 1 | $24 |
| Welch Allyn | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Profound Medical Corp. | 1 | $19 |
| Medtronic | 1 | $18 |
| KARL Storz Endoscopy-america | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Cook Medical LLC | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Olympus America Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,197
- SOLYX$772
- CVAC Aspiration System$173
- XIAFLEX$122
- ADSTILADRIN$122
- Bulkamid$113
- Axonics$113
- NOCDURNA$112
- UroLift System$110
How this compares
$6,146 in reported general payments places this provider in the 65th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 260 | $192,303 |
| GemtesaVibegron | 32 | $27,609 |
| Methenamine Hippurate | 135 | $15,631 |
| Potassium Citrate ErPotassium Citrate | 83 | $6,689 |
| Tamsulosin Hcl | 317 | $2,518 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $1,399 |
| Testosterone Cypionate | 37 | $1,285 |
| Cephalexin | 176 | $1,048 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 144 | $729 |
| Cefdinir | 39 | $537 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $396 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $307 |
| Oxycodone Hcl | 113 | $303 |
| Finasteride | 17 | $232 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $445 | $192,303260 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $107 | $27,60932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 96 urology providers in Utah.
Other urology in West Jordan
- Brandon ChildsWest Jordan$3K
- Steven GangeSlc$1.5M
- William BrantSalt Lake City$290K
- Roscoe NelsonAmerican Fork$152K
- Nathan PursifullAmerican Fork$86K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Jeffrey SparenborgProvo$37K
- Daniel SimonRiverton$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.